Journal of Advanced Pharmaceutical Technology & Research

: 2022  |  Volume : 13  |  Issue : 3  |  Page : 187--190

Curcumin: Boosting the immunity of COVID-19-vaccinated populations

Sry Suryani Widjaja1, Rusdiana Rusdiana1, Rina Amelia2,  
1 Department of Biochemistry, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
2 Department of Community Medicine/Public Health, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia

Correspondence Address:
Dr. Sry Suryani Widjaja
Jl. Joserizal No. 33E/51, Medan 20214


The ongoing, highly infectious COVID-19 pandemic has prompted various drugs, vaccines, and phytochemical research to control the disease. The accelerated development of vaccines showed the importance of immune boosters against the virus. This study aims to elucidate the role of curcumin, a phytochemical with an immunoediting profile potentially able to boost immunity after vaccination. Eighty participants were enrolled to receive curcumin supplementation (n = 40) and without (n = 40) after the first vaccination until 4 weeks after the second vaccination. Total antibody formation for SARS-CoV-2 was measured using an enzyme-linked immunosorbent assay 4 weeks after the second vaccination. The average antibody formed in groups treated with curcumin supplementation showed a statistically significant increase compared to the control group (262.6 ± 324.2 vs. 42.8 ± 53.5, P < 0.01). Age, sex, and comorbidities did not affect the production of antibodies within groups. Curcumin showed potential as a complementary supplementation during the period of vaccination as it can increase antibodies produced post vaccinations. Further investigation should be conducted on more subjects and a longer period in concordance to vaccine boosters and emerging new variants.

How to cite this article:
Widjaja SS, Rusdiana R, Amelia R. Curcumin: Boosting the immunity of COVID-19-vaccinated populations.J Adv Pharm Technol Res 2022;13:187-190

How to cite this URL:
Widjaja SS, Rusdiana R, Amelia R. Curcumin: Boosting the immunity of COVID-19-vaccinated populations. J Adv Pharm Technol Res [serial online] 2022 [cited 2022 Oct 5 ];13:187-190
Available from:

Full Text


The emerging novel coronavirus disease or known as COVID-19 was first discovered in China, Wuhan City, in December 2019, rapidly turned into a global pandemic. The high transmissibility and its varying spectrum of severity cause high mortality and morbidity in infected patients.[1],[2] COVID-19 was announced by the WHO as an international health emergency as the number of cases surged to 352 million cases worldwide, with the death toll exceeding 1.6 million cases in late January 2022.[3] COVID-19 is a disease caused by RNA betacoronavirus which has similarities to SARS-CoV.[4],[5] In Indonesia, COVID-19 was detected in early March 2020. Insofar, as more than 4.2 million cases have been recorded, with a death toll of 144,000 cases.[6] The colossal effect of COVID-19 in every aspect of life has urged the world to immediately develop various types of vaccines and treatment plans which were expected to control the disease.

Our body's immune system is by far the best defense against various microorganisms invasions. With a properly functioning immune system, infections would be resolved appropriately.[7] The COVID-19 treatment plans, apart from antivirals, are accompanied by the provision of nutrients and supplements aimed to overcome inflammation, oxidative stress, and cytokine storms.[8] Several types of phytochemicals can reduce the severity of viral infections, their anti-inflammatory, antioxidants, and antiviral effects, thus improving immunity.[8],[9] These nutrients are utilized to overcome various pathological effects caused by COVID-19 infection, so the use of these natural components can be alternative prevention or supportive treatment of COVID-19.[10]

The curcumin (diferuloylmethane) found in turmeric (Curcuma longa) has antibacterial, antiviral, antifungal, as well as antioxidant and anti-inflammatory effects.[11] The antioxidant effect of curcumin is obtained by neutralization of free radicals and increasing antioxidant enzyme production, thus hinting at a potential for COVID-19 treatment.[2],[10],[12] In a systematic review of six randomized controlled trials on 558 patients, curcumin as an adjunct therapy in COVID-19 patients improved clinical outcomes and reduced hyperinflammatory effects.[13]

The dose-dependent immunoediting potential of curcumin to suppress or increase T-cell production has also been recognized in several cases.[14] Not only Treg inhibition but curcumin also increase the function of effector T-cells. Curcumin treatment on myeloid-derived suppressor cells showed an increment in CD8 + T-cell number and reduction of Treg cells, enhancing antitumor immune response.[15] The role of curcumin in enhancing immunity has also been documented in several clinical investigations. In both colon and lung cancer studies, curcumin therapy increases Th1 cells by promoting Treg cell conversion to Th1 cells and markedly decreases Treg cells through Foxp3 suppression and expression of IFN-γ.[16],[17]

More studies were put on the effects of curcumin on T-cells and the immune system. However, very few nonanimal studies can be found to support the effect of curcumin on B memory cell production, which contributed to humoral immunity producing antibodies. This study aims to elucidate the difference in antibody formation between vaccinated populations subjected to routine turmeric powder supplement compared to subjects who did not receive turmeric supplementation.

 Materials and Methods

This investigation was performed in a cohort of 80 recipients of the COVID-19 vaccine enrolled from March to October 2021. In the test group (n = 40), each subject was given 5 g of turmeric powder to be consumed daily for 8 weeks by diluting the powder in 150 ml of room-temperature water. The control group (n = 40) did not receive any supplementation. Exclusion criteria included COVID-19, pregnancy, or malignancy during the study period. All subjects were administered two doses (0.5 ml each) of CoronaVac® vaccine 4 weeks apart. The assessment for quantitative COVID-19 spike receptor-binding domain antibodies (S-RBD) was carried out using the enzyme-linked immunosorbent assay 4 weeks after the second dose.

Blood sera samples from patients were obtained under the protocols approved by the Ethical Committee through the Institutional Review Board of Universitas Sumatera Utara, Indonesia (Ethical Clearance No. 526/KEP/USU/2021). All participants had signed the informed consent and the research had been carried out according to the Declaration of Helsinki.


Among the total of 80 participants enrolled, 40 postvaccinated patients were given a solution of 5 g of turmeric powder. Measurement of quantitative RBD SARS-CoV-2 antibody was carried out 4 weeks after the second vaccine administration. “Characteristic of patients were shown in [Table 1].{Table 1}

The results showed a statistically significant difference in the value of the quantitative RBD SARS-CoV-2 antibody level between the postvaccine group that was given turmeric powder compared to the control group (P ≤ 0.01), while age, sex, body mass index, and the presence of comorbidities did not. The average antibody level measured across the subjects was 152.2 IU/ml.


Amid the COVID-19 pandemic, it is essential to keep up with the urgency on preventive measures, cures, and a keener effort to elucidate the role and formulations of herbs. The health-promoting effect of curcumin has been well established in traditional medicine practices. Curcumin shows a significant role in the immune system through gene and enzyme modulations for disease prevention as well as a supplementary treatment. This study is the first study to investigate the effectiveness of curcumin on immune system stimulation in the vaccinated COVID-19 population.

Curcumin exerts its immune-boosting effects through free radical neutralization and antioxidant enzyme enhancement.[10] The inflammatory modulation actions of curcumin in COVID-19 pathogenesis commenced by inhibition of inflammatory transcription factors such as signal transducer and activator of transcription-3, nuclear factor kappa B, and downregulation of proinflammatory cytokines.[18],[19] During SARS-CoV-2 infection, curcumin inhibits angiotensin-converting enzyme 2 synthesis, which further promotes anticoagulation and fibrinolysis to prevent severe COVID-19.[8],[9],[20],[21] Curcumin has also shown promising effects on numerous viral infections including human immunodeficiency virus, influenza, herpes simplex virus, and hepatitis.[18],[19],[22],[23],[24] Despite plenty of research on the role of curcumin as a potential treatment, supplement, and safe option for improving COVID-19 disease outcomes, the effect on curcumin supplementation postvaccine has not been demonstrated.[19]

To combat the outbreak, there were loads of developed COVID-19 vaccines, including mRNA vaccine, inactivated vaccine, and viral vector vaccine.[25] After immunization, the antigen presented in the vaccine triggers B-cells which divide and mature into memory B-cells and polyclonal plasma B-cells. Antibodies would then be produced into IgM, the first antibody to emerge during the primary immune response, and IgG, a more effective antibody for opsonization and neutralizing antibody.[26] The number of B-cells producing antibodies could be T-cell-dependent or independent. During the extrafollicular process of IgM production, T-cells contribute during B- and T-cell crosstalk at the germinal center; B-cells would be then able to switch from IgM to other isotopes as well as to improve B-cell receptor affinity against antigens. These antibodies would then efficiently neutralize the SARS-CoV-2 virus.[27],[28]

The present study showed a significant increase in SARS-CoV-2 antibody production in the test group consuming 5 g of curcumin powder. Studies have reported varying levels of antibody response as a measure of the effectiveness of the vaccine.[29],[30] After COVID-19 vaccination, a study reported an increment of antibody observed after 2 weeks, with a median of 234–580 IU/ml. However, it is also observed that 66% of subjects demonstrated <10 IU/ml antibody after the first vaccination dose. Similar to this study, the second dose of vaccination improves the antibody level from a median of 40–4320 IU/ml without any nonresponders (<10 IU/ml). The variability of vaccines is also attributed to sex, with females producing higher antibodies compared to males in which the gap shortens after 1 month. In regard to age, the antibodies produced were found to be inversely correlated with age.[30]


In summary, this study was the first to explore the effect of curcumin to improve antibody produced post-COVID-19 vaccination. Curcumin supplementation yields a higher measured antibody after vaccination which is independent of age, sex, and comorbidities. Further research with more subjects and variables has to be accounted for to establish a proper causal relationship between curcumin supplementation with antibody produced post-COVID-19 vaccination.


This study was supported by the research grant TALENTA, Ministry of Research and Technology and Higher Education Republic Indonesia.

Financial support and sponsorship

This study was supported by the research grant TALENTA, Ministry of Research and Technology and Higher Education Republic Indonesia.

Conflicts of interest

There are no conflicts of interest.


1Baric RS. Emergence of a highly fit SARS-CoV-2 variant. N Engl J Med 2020;383:2684-6.
2Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708-20.
3WHO. Coronavirus disease (COVID-19) outbreak [internet]. [2022; cited 2022 Feb 5]. Available from:
4Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 2020;395:565-74.
5Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727-33.
6WHO. Coronavirus disease (COVID-19) – Indonesia [internet]. [2022; cited 2022 Feb 9]. Available from:
7Zhou X, Ye Q. Cellular immune response to COVID-19 and potential immune modulators. Front Immunol 2021;12:646333.
8Khanna K, Kohli SK, Kaur R, Bhardwaj A, Bhardwaj V, Ohri P, et al. Herbal immune-boosters: Substantial warriors of pandemic COVID-19 battle. Phytomedicine 2021;85:153361.
9Jamiu AT, Aruwa CE, Abdulakeem IA, Ayokunnun Ajao A, Sabiu S. Phytotherapeutic evidence against coronaviruses and prospects for COVID-19. Pharmacogn J 2020;12:1252-67.
10Mrityunjaya M, Pavithra V, Neelam R, Janhavi P, Halami PM, Ravindra PV. Immune-boosting, antioxidant and anti-inflammatory food supplements targeting pathogenesis of COVID-19. Front Immunol 2020;11:570122.
11Catanzaro M, Corsini E, Rosini M, Racchi M, Lanni C. Immunomodulators inspired by nature: A review on curcumin and echinacea. Molecules 2018;23:E2778.
12Malik P, Mukherjee TK. Structure-function elucidation of antioxidative and prooxidative activities of the polyphenolic compound curcumin. Chin J Biol 2014;2014:1-8.
13Vahedian-Azimi A, Abbasifard M, Rahimi-Bashar F, Guest PC, Majeed M, Mohammadi A, et al. Effectiveness of curcumin on outcomes of hospitalized COVID-19 patients: A systematic review of clinical trials. Nutrients 2022;14:256.
14Bose S, Panda AK, Mukherjee S, Sa G. Curcumin and tumor immune-editing: Resurrecting the immune system. Cell Div 2015;10:6.
15Liao F, Liu L, Luo E, Hu J. Curcumin enhances anti-tumor immune response in tongue squamous cell carcinoma. Arch Oral Biol 2018;92:32-7.
16Xu B, Yu L, Zhao LZ. Curcumin up regulates T helper 1 cells in patients with colon cancer. Am J Transl Res 2017;9:1866-75.
17Zou JY, Su CH, Luo HH, Lei YY, Zeng B, Zhu HS, et al. Curcumin converts Foxp3+regulatory T cells to T helper 1 cells in patients with lung cancer. J Cell Biochem 2018;119:1420-8.
18Xu Y, Liu L. Curcumin alleviates macrophage activation and lung inflammation induced by influenza virus infection through inhibiting the NF-κB signaling pathway. Influenza Other Respir Viruses 2017;11:457-63.
19Dhar S, Bhattacharjee P. Promising role of curcumin against viral diseases emphasizing COVID-19 management: A review on the mechanistic insights with reference to host-pathogen interaction and immunomodulation. J Funct Foods 2021;82:104503.
20Rattis BA, Ramos SG, Celes MR. Curcumin as a potential treatment for COVID-19. Front Pharmacol 2021;12:675287.
21Kritis P, Karampela I, Kokoris S, Dalamaga M. The combination of bromelain and curcumin as an immune-boosting nutraceutical in the prevention of severe COVID-19. Metabol Open 2020;8:100066.
22Šudomová M, Hassan ST. Nutraceutical curcumin with promising protection against herpesvirus infections and their associated inflammation: Mechanisms and pathways. Microorganisms 2021;9:292.
23Ailioaie LM, Litscher G. Curcumin and photobiomodulation in chronic viral hepatitis and hepatocellular carcinoma. Int J Mol Sci 2020;21:E7150.
24Farzaei MH, Zobeiri M, Parvizi F, El-Senduny FF, Marmouzi I, Coy-Barrera E, et al. Curcumin in liver diseases: A systematic review of the cellular mechanisms of oxidative stress and clinical perspective. Nutrients 2018;10:E855.
25Kaur SP, Gupta V. COVID-19 vaccine: A comprehensive status report. Virus Res 2020;288:198114.
26Pollard AJ, Bijker EM. A guide to vaccinology: From basic principles to new developments. Nat Rev Immunol 2021;21:83-100.
27Diks AM, Overduin LA, van Leenen LD, Slobbe L, Jolink H, Visser LG, et al. B-Cell immunophenotyping to predict vaccination outcome in the immunocompromised – A systematic review. Front Immunol 2021;12:690328.
28Luo W, Yin Q. B cell response to vaccination. Immunol Invest 2021;50:780-801.
29Ciarambino T, Para O, Giordano M. Immune system and COVID-19 by sex differences and age. Womens Health (Lond) 2021;17:17455065211022262.
30Wheeler SE, Shurin GV, Yost M, Anderson A, Pinto L, Wells A, et al. Differential antibody response to mRNA COVID-19 vaccines in healthy subjects. Microbiol Spectr 2021;9:e0034121.